Having identified and characterized PIPE-791 as an LPA1 selective antagonist in both in vitro and in vivo contexts, we sought to better understand LPA1 expression CNS, particularly in the context of multiple sclerosis. Here, LPAR1 is linked to multiple sclerosis.